Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Micro-fragmented adipose tissue for the treatment of hip osteoarthritis: A prospective pilot study at 1-year follow-up

Zaffagnini M., Raggi F., Carillo E., Andriolo L., Boffa A., Cavallo C.

Prospective Study with a reported sample of 19 on Osteoarthritis, Hip Osteoarthritis, published in J Exp Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Exp Orthop (2025)
Reported sample size
19
Source database
Europe PMC
PMID
41473851
PMCID
PMC12745173
DOI
10.1002/jeo2.70579

Abstract (original English)

Purpose Micro-fragmented adipose tissue (MFAT) has been proposed as a promising option for hip osteoarthritis (OA). The aim of this prospective study was to evaluate clinical outcomes of MFAT injections in patients with hip OA. Methods Thirty patients (19 men and 11 women, 55.7 ± 8.2 years) with symptomatic hip OA (Tönnis Grade 1-2) were treated with a single ultrasound-guided MFAT injection. Patients were evaluated at baseline and 1-3-6-12 months of follow-up with the Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), and Harris Hip Score (HHS). Adverse events were also documented. MFAT samples were evaluated for cell analysis and characterization. Results No major complications were reported, and only three patients failed. The total WOMAC score significantly improved from baseline (31.2 ± 16.4) only at 1 month (21.0 ± 14.3, p = 0.015) and 3 months (19.3 ± 15.8, p = 0.012), while VAS and HHS scores showed a significant improvement from baseline to all follow-ups. The minimal clinically important difference (MCID) for the total WOMAC score was achieved in 56.7% of patients at 6 and 12 months. Better clinical improvement and MCID achievement were observed in mild compared to moderate hip OA. A total of 300.000 cells derived from MFAT produced small colonies from Day 10 (89.9 ± 61.2), increasing by Day 20 (129.9 ± 47.9). Conclusions A

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research